ALTME Stock Overview A clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
TME Pharma N.V. Competitors Price History & Performance
Summary of share price highs, lows and changes for TME Pharma Historical stock prices Current Share Price €0.072 52 Week High €0.44 52 Week Low €0.061 Beta 1.61 1 Month Change -4.87% 3 Month Change -47.84% 1 Year Change -66.61% 3 Year Change -99.71% 5 Year Change -99.85% Change since IPO -100.00%
Recent News & Updates TME Pharma N.V. has filed a Follow-on Equity Offering in the amount of €2.6 million. Dec 05
TME Pharma N.V. has filed a Follow-on Equity Offering. Dec 04
TME Pharma Receives €2.4 Million German Federal Ministry of Education and Research Grant to Support NOX-A12 Phase 2 Trial in Brain Cancer Nov 01
TME Pharma Receives €2.4 Million German Federal Ministry of Education and Research Grant to Support NOX-A12 Phase 2 Trial in Brain Cancer Oct 31
TME Pharma N.V. Provides Clinical Update Oct 18
TME Pharma N.V. Announces Appointment of Alexandra Glucksmann to Supervisory Board Oct 01 See more updates TME Pharma N.V. has filed a Follow-on Equity Offering in the amount of €2.6 million. Dec 05
TME Pharma N.V. has filed a Follow-on Equity Offering. Dec 04
TME Pharma Receives €2.4 Million German Federal Ministry of Education and Research Grant to Support NOX-A12 Phase 2 Trial in Brain Cancer Nov 01
TME Pharma Receives €2.4 Million German Federal Ministry of Education and Research Grant to Support NOX-A12 Phase 2 Trial in Brain Cancer Oct 31
TME Pharma N.V. Provides Clinical Update Oct 18
TME Pharma N.V. Announces Appointment of Alexandra Glucksmann to Supervisory Board Oct 01
TME Pharma N.V. Appoints Lee Schalop as Member of the Supervisory Board Jun 28
New major risk - Negative shareholders equity Apr 28
TME Pharma N.V. Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two-Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer Apr 23
TME Pharma N.V. Receives US FDA Fast Track Designation for Lead Asset NOX-A12 in Brain Cancer Apr 03
TME Pharma N.V. Announces FDA Clearance of Investigational New Drug (Ind) Application for Nox-A12 Phase 2 Trial in Brain Cancer Mar 06 TME Pharma N.V. announced that it expects to receive €1.479999 million in funding Feb 09
TME Pharma Announces Successful Advice Meeting with US Food and Drug Administration on Nox-A12 Development in Brain Cancer Jan 10 TME Pharma N.V. announced that it has received €2.7 million in funding Dec 14
TME Pharma N.V. Provides Positive Update on 18-Month Survival for NOX-A12 Combination Regimen in Brain Cancer Oct 10
TME Pharma Announces Selection of Two Clinical Abstracts on the Ongoing NOX-A12 GLORIA Phase 1/2 Trial in Glioblastoma for Presentation at ESMO 2023 Congress and SNO 2023 Annual Meeting Sep 22
Tme Pharma N.V. Announces NOX-A12 Combination Regimen with Bevacizumab: 17-Month Survival Rate Exceeds All Relevant Competitor Treatments Against Most Severe Form of Adult Brain Cancer Sep 13
TME Pharma N.V. Provides Positive Data Update on Best Response to Therapy with First Complete Response in Glioblastoma, Bringing 50% of Patients in Expansion Arm to Complete or Near- Complete Response Jul 13
TME Pharma N.V. Announces Positive 15-Month Survival Data from Gloria Expansion Arm Evaluating NOX-A12 in Combination with Radiotherapy and Bevacizumab in Glioblastoma Jun 30
TME Pharma N.V. Receives Investigational New Drug (IND) Approval for NOX-A12 From the US FDA Jun 16
TME Pharma N.V., Annual General Meeting, Jun 29, 2023 May 30
TME Pharma N.V. Provides Positive Clinical Update and 14-Month Survival Data from Gloria Expansion Arm Evaluating Nox-A12 in Combination with Radiotherapy and Bevacizumab in Glioblastoma May 26
Tme Pharma Provides Clinical Update on the Gloria Expansion Arm Testing Nox-A12 in Combination with Radiotherapy and Bevacizumab in Patients with Glioblastoma Jan 23 TME Pharma N.V. Announces Executive Changes
TME Pharma Announces Positive Updated Interim Results from NOX-A12 GLORIA Phase 1/2 in Brain Cancer Presented at the Society for Neuro-oncology 2022 Annual Meeting Nov 19
TME Pharma Announces Publication of Abstract Disclosing Positive Interim Results from Bevacizumab Expansion Arm of NOX-A12 Gloria Phase 1/2 Brain Cancer Clinical Trial Nov 12
TME Pharma N.V. Announces Data Safety Monitoring Board Validated Safety Data from the Initial Four Weeks of Treatment of the First Patient Enrolled in the GLORIA Phase 1/2 Clinical Trial Expansion Arm with NOX A12 Aug 26
TME Pharma Announces Enrollment of First Patient in Pembrolizumab Expansion Arm of NOX-A12 GLORIA Phase 1/2 Brain Cancer Clinical Trial Aug 04
NOXXON Pharma N.V. Announces Resignation of Gregory Weaver from its Supervisory Board, Effective September 30, 2022 Jul 13
NOXXON Announces Updated Development Strategy Following Strong Clinical Benefit Observed With NOX-A12 in Combination With Radiotherapy and Bevacizumab in Brain Cancer Jun 23
NOXXON Pharma N.V., Annual General Meeting, Jun 29, 2022 May 30
NOXXON Announces Presentation of NOX-A12 Phase 1/2 Data in Glioblastoma at The 2022 ASCO Annual Meeting and Invitation to a Dedicated KOL Event May 27
Noxxon Pharma N.V. Announces Scientific Advisory Board Appointments May 12
Price target decreased to €0.83 Apr 27
Top-Line Results from NOXXON’S NOX-A12 Phase 1/2 GLORIA Trial in Brain Cancer to Be Presented during 2022 ASCO Annual Meeting Apr 06
NOXXON Provides Progress Update on the Expansion Arms of the Phase 1/2 GLORIA Trial With NOX-A12 in Brain Cancer Patients Jan 07
NOXXON Pharma N.V. announced that it expects to receive €17 million in funding from Atlas Special Opportunities LLC Jan 04
Will NOXXON Pharma (EPA:ALNOX) Spend Its Cash Wisely? Dec 20
NOXXON Pharma N.V. Announces Enrolment of First Patient in the Expansion of the NOX-A12 Phase 1/2 Trial in Brain Cancer Dec 09
NOXXON Pharma N.V. Presents New Phase 1/2 Data On NOX-A12 & Radiotherapy Combination in Brain Cancer at the Society for Neuro-Oncology Annual Meeting 2021 Nov 23
NOXXON Pharma N.V Enrolls Last Brain Cancer Patient in Dose Escalation Portion of GLORIA Study and Confirms Phase 1/2 Read-Out Sep 23
We're Keeping An Eye On NOXXON Pharma's (EPA:ALNOX) Cash Burn Rate Sep 06
NOXXON Provides Update on NOX-A12 Clinical Programs Aug 06
Member of Supervisory Board J. deBethizy has left the company Jul 02
Independent Member of the Supervisory Board Bertram Köhler has left the company Jul 02
NOXXON Pharma N.V. Announces Positive Results from the Second Cohort in its Phase 1/2 Study of Nox-A12 Jun 09
NOXXON Announces Positive Results From Second Cohort in Phase 1/2 NOX-A12 Brain Cancer Trial Jun 01
Is NOXXON Pharma (EPA:ALNOX) In A Good Position To Invest In Growth? May 19
Noxxon Pharma N.V. Announces Data Safety Monitoring Board Validates NOX-A12 Highest Dose in Phase 1/2 Brain Cancer Trial May 11
Noxxon Pharma N.V. Announces That the Data Safety Monitoring Board Analyzed Safety Data from the Initial Four Weeks of Treatment of the First Patient Enrolled in the Third and Final Dose Cohort of the NOX-A12 Plus Mar 14
NOXXON Enrolls First Patient in the High Dose Cohort of Trial Combining NOX-A12 With Radiotherapy in Newly Diagnosed Brain Cancer Feb 16
NOXXON Appoints Leading Pancreatic Cancer Experts to Scientific Advisory Board Feb 09
NOXXON Pharma N.V. Appoints Jose Saro as Chair of Scientific Advisory Board Feb 02
NOXXON Pharma (EPA:ALNOX) Is In A Good Position To Deliver On Growth Plans Feb 01
New 90-day high: €0.61 Jan 20
New 90-day high: €0.57 Dec 30
NOXXON Pharma N.V. Announces Initiation of NOX-A12 Manufacturing for Future Clinical Studies Dec 30
New 90-day high: €0.56 Nov 30
NOXXON Pharma N.V. Announces That Data Safety Monitoring Board Validates Further Nox-A12 Dose Escalation in Phase 1/2 Brain Cancer Study Nov 09
NOXXON Pharma N.V. Announces Completion of 6-Month Therapy for Low-Dose Cohort in Phase 1/2 Brain Cancer Study of NOX-A12 Plus Radiotherapy Oct 29
Noxxon Pharma N.V. Announces Three Additional Clinical Centers to Recruit Patients for Nox-A12 Brain Cancer Trial Oct 20
New 90-day low: €0.45 Oct 15
Noxxon Announces Successful Completion of Patient Recruitment for Second Dose Cohort in Phase 1/2 Brain Cancer Study of Nox-A12 Plus Radiotherapy Oct 14
NOXXON Pharma N.V. Presents Final Clinical Data from Phase 1/2 NOX-A12 / Keytruda® Combination Trial in Colorectal and Pancreatic Cancer at the ESMO Virtual Congress 2020 Sep 17
NOXXON Pharma N.V. announced that it has received €0.499999 million in funding Jul 23 Shareholder Returns ALTME FR Biotechs FR Market 7D -4.9% -3.0% 4.1% 1Y -66.6% -27.9% 3.7%
See full shareholder returns
Return vs Market: ALTME underperformed the French Market which returned 4.3% over the past year.
Price Volatility Is ALTME's price volatile compared to industry and market? ALTME volatility ALTME Average Weekly Movement 17.1% Biotechs Industry Average Movement 7.2% Market Average Movement 4.5% 10% most volatile stocks in FR Market 9.3% 10% least volatile stocks in FR Market 2.4%
Stable Share Price: ALTME's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: ALTME's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. The company is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy.
Show more TME Pharma N.V. Fundamentals Summary How do TME Pharma's earnings and revenue compare to its market cap? ALTME fundamental statistics Market cap €6.81m Earnings (TTM ) -€6.32m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ALTME income statement (TTM ) Revenue €0 Cost of Revenue €0 Gross Profit €0 Other Expenses €6.33m Earnings -€6.32m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/20 12:14 End of Day Share Price 2025/01/17 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources TME Pharma N.V. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jean-Pierre Loza In Extenso Financement & Marché Benjamin Isaacson Scotiabank Global Banking and Market
Show 0 more analysts 
